Rep: If Arkansas can do this, so can Massachusetts
'One last thing I'll leave you with: The state of Arkansas, in March, just passed a comprehensive [cognitive rehabilitation therapy] bill. And if Arkansas can do it, I'm absolutely positive Massachusetts will be doing it soon,' the Holden Republican said, drawing chuckles from the committee and attendees.
The legislation Ferguson pitched (H 1151 / S 742) would extend Group Insurance Commission and commercial health insurance coverage for cognitive rehabilitation therapy to people with an acquired brain injury, which Ferguson said could range from a severe concussion to a traumatic brain injury sustained in a car crash.
'This bill is, now more than ever, critical to get passed so that we can require the coverage for CRT, cognitive rehab therapy, for these patients. And it also will help their families and caregivers as well,' Ferguson, who worked as a speech pathologist with people who had acquired brain injuries, said. 'And as we know, early intervention is key to get these skills back and help folks recover as best as they can.'
Ferguson said expanding access to CRT in cases of acquired brain injury was one of the unanimously-supported recommendations of the state's Brain Injury Commission that dates back to at least fiscal year 2011. That group's 2021 report said the Center for Health Information and Analysis analyzed a previous version of Ferguson's bill and found that the impact on the typical member's monthly health insurance premium would be between 1 cent and 19 cents, or an average cost of 8 cents per month.
The idea has cleared the Financial Services Committee in each of the last four sessions and has twice (the 2017-18 and 2021-22 sessions) been reported favorably out of the Health Care Financing Committee, according to a committee bill summary. But it has not been debated in either branch.
It is likely in line for another favorable report from Financial Services — co-chair Sen. Paul Feeney sponsored the Senate version of the legislation and said Tuesday he's hopeful that 'we get enough momentum to get it over the finish line' this time around.
Resistance has come from the Massachusetts Association of Health Plans, whose leader voiced her opposition to the insurance mandate earlier this year, warning it would raise costs for consumers and small businesses.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
San Francisco Chronicle
16 minutes ago
- San Francisco Chronicle
FDA names former pharmaceutical company executive to oversee US drug program
WASHINGTON (AP) — The Food and Drug Administration on Monday named a longtime pharmaceutical executive to run the agency's drug program, the latest in a string of leadership changes at the agency. FDA Commissioner Marty Makary announced that Dr. George Tidmarsh, a cancer and pediatric specialist, will direct the agency's Center for Drug Evaluation and Research, which regulates the safety and effectiveness of all U.S. drugs. His appointment comes a month after the center's acting director, Dr. Jacqueline Corrigan-Curay, announced her retirement. As the agency's top drug regulator, Tidmarsh will be charged with following through on a number of commitments made by Makary and his boss, Health Secretary Robert F. Kennedy Jr., including reviewing the safety of the abortion pill mifepristone. The FDA is also scrutinizing certain uses of other long-established drugs, including antidepressants and hormone-replacement drugs for menopause. Tidmarsh founded and led several pharmaceutical companies, including Horizon Pharmaceuticals, maker of an anti-inflammatory medication for arthritis. He has also served as an adjunct professor at Stanford University. The FDA's drug center is the agency's largest unit, with nearly 6,000 staffers responsible for reviewing the safety and effectiveness of new drugs and monitoring the use and marketing of older drugs. About 2,000 FDA staffers have been laid off as part of widescale cuts to the federal health workforce overseen by Kennedy. More than 1,000 others have taken buyouts or early retirement, while many others are reportedly searching for new jobs. The departures have threatened basic FDA operations, including the timely review of new drugs. Nearly all of the FDA's senior leadership positions have turned over in recent months, either due to retirements, resignations or actions by administration officials placing them on administrative leave. FDA center directors typically hold their positions for years or even decades, serving across multiple administrations, whether Republican or Democrat. In May, Makary named Dr. Vinay Prasad, a prominent critic of the FDA's COVID response, to run the agency's vaccine center. He was also named to the post of FDA chief medical officer. Prasad joined the agency after his predecessor, longtime vaccine chief Dr. Peter Marks, was forced out in March. The head of FDA's tobacco center was also forced to step down in April. A permanent replacement has not yet been named. ___ The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute's Department of Science Education and the Robert Wood Johnson Foundation. The AP is solely responsible for all content.
The Hill
13 hours ago
- The Hill
We can't win the fight to end HIV if we cut funding and access to medication
The fight to end HIV in our lifetimes just received a game-changing innovation. In June, the FDA approved Yeztugo (lenacapavir), a groundbreaking HIV prevention treatment that requires just two injections per year — and scored 99 percent effectiveness in trials. This monumental scientific breakthrough is poised to transform the lives of people who have found it hard to keep up with daily oral pre-exposure prophylaxis, providing an option that fits better into their everyday lives. But as exciting as this development is, it could be undermined by the Trump administration's proposal to cut nearly $1 billion from federal HIV prevention programs. Innovations like lenacapavir could be a key tool to ending the epidemic, but only if we have the resources and policy to deliver it directly to those who need them most. Although lenacapavir's efficacy is groundbreaking, access remains another story. With a price tag hovering around $28,000 a year, this medication risks being out of reach for the very communities who need it most. We're still waiting to see how programs managed by Gilead Sciences, which developed the treatments, and the broader insurance markets will step up. And it's not just the cost of the drug itself. It's the labs, the provider visits, the follow-ups — each one a potential roadblock for someone trying to stay safe. Federal leadership is essential to ensuring this new HIV prevention tool reaches the communities who need it most. This includes updating clinical guidelines, funding support services and supporting the infrastructure that makes access possible. Unfortunately, the Trump administration and the Republican majorities in Congress are putting access to lifesaving innovations at risk. The administration's attacks on HIV prevention, including its proposals to eliminate the Centers for Disease Control and Prevention's HIV budget and efforts to dismantle public health systems, threaten progress. The Republican budget reconciliation bill that President Trump signed over the July 4 weekend includes deep cuts to Medicaid — the largest payer for HIV care in the U.S. Without strong federal investment and coordination, expanding access to new tools and ending the HIV epidemic is at serious risk. Despite the real strides we have made in HIV prevention, those of us in the lesbian, gay, and transgender community — especially non-white Southerners in rural areas or navigating poverty — know that not every prevention strategy reaches us, works for us, or is built with us in mind. Our realities demand options that reflect the full truth of who we are and how we live. Lenacapavir offers real, powerful hope, but let's be clear: Science alone won't save us. What will make the difference is equitable and intentional policies that center our communities and a public health infrastructure that doesn't leave us behind. These numbers don't shift on their own. Yes, we have made progress over time. But the hard truth is that Black Americans still account for 43 percent of all new HIV diagnoses in the U.S., despite being just 13 percent of the population. The data is even more stark for Black transgender women: 44 percent are living with HIV, and their lifetime risk remains unacceptably high. And we cannot ignore the geography of this epidemic. The South accounts for 52 percent of all new HIV diagnoses in the U.S. That's not a coincidence — it is the result of systemic failures: limited access to healthcare, persistent stigma, lack of comprehensive sex education and the absence of strong non-discrimination protections. These barriers don't just prevent care — they trap people in cycles where prevention tools are out of reach. Among gay and bisexual Black men, the risk of contracting HIV is still 50 percent over a lifetime. Prevention tools like pre-exposure prophylaxis and lenacapavir hold promise, but they only matter if people can actually access them, without fear, shame or coercion. Ending this epidemic means creating environments where people are safe to make informed choices about their own health. The fight to end the HIV epidemic is not just about what happens in labs — it's about how we make these innovations real for our communities. Science is doing its part. Now is the time to urge Congress to reject any cuts to CDC HIV prevention efforts and to fully fund the HIV response. We have the tools to end this epidemic, but not if we dismantle the very systems our communities rely on to survive. The promise of lenacapavir, and the hope it represents, is too great to let fall through the cracks of policy neglect. The question is, will we make the choice to ensure that this breakthrough reaches all of us? Science has given us the tools. Now, we must ensure that everyone has the opportunity to use them.
Los Angeles Times
a day ago
- Los Angeles Times
Federal cuts leave Los Angeles County health system in crisis
Los Angeles County's health system, which is responsible for the care of the region's poorest, is careening toward a financial crisis because of cuts from a presidential administration and Republican-led Congress looking to drastically slash the size of government. President Trump's 'Big Beautiful Bill,' which passed earlier this month, is expected to soon claw $750 million per year from the county Department of Health Services, which oversees four public hospitals and roughly two dozen clinics. In an all-staff email Friday, the agency called the bill a 'big, devastating blow to our health system' and said a hiring freeze had gone into effect, immediately. And the Trump administration's budget for the next fiscal year will likely result in a $200-million cut to the county Department of Public Health, whose responsibilities include monitoring disease outbreaks, inspecting food and providing substance use treatment. 'I'm not going to sugarcoat it. I'm not going to say we survive this,' said Barbara Ferrer, head of the public health department, in an interview. 'We can't survive this big a cut.' Both Ferrer and Department of Health Services head Christina Ghaly warned that the federal cuts will devastate their agencies — and the patients they serve — for years to come. Employee layoffs are likely. In April, the White House announced it was ending infectious disease grants worth billions of dollars, including $45 million that L.A. County was supposed to use to combat the spread of measles and bird flu. California has joined other states in a lawsuit fighting the cuts, and the court has issued a preliminary injunction suspending the cuts. This month, the county public health department lost another $16 million after Trump's bill cut funding for a program educating food stamp recipients about how to buy healthy meals. And there's more to come. The Trump administration's proposed budget for 2026 will be the biggest blow yet, Ferrer warned, yanking $200 million from her department — a 12% cut. 'I'm old. I've been around for a long time,' said Ferrer, whose work in public health dates back to the Reagan administration. 'I've never actually seen this much disdain for public health.' Ferrer said the cuts mean she no longer has enough money for the county's bioterrorism watch program, which monitors for outbreaks that might signal a biological attack. Soon, she said, county officials may have to stop testing ocean water for toxins year round, cutting back to just half the year. 'Like, you want to swim? You want to know that the water is safe where you swim, then oppose these kinds of cuts,' she said. 'That affects everybody who goes to the beach.' Layoffs are likely, said Ferrer. About 1,500 public health staffers are supported through federal grants. More than half the federal money the department receives is funneled to outside organizations, which would likely need to make cuts to stay afloat. A similarly grim cost analysis is underway at the county Department of Health Services, where executives said they expect to lose $280 million this fiscal year because of the bill. 'I can't make a promise that we will be able to avoid layoffs because of the magnitude of the challenges,' said Ghaly. Ghaly said the bill slashed the extra Medicaid money the county typically gets to cover care for low-income patients. They expect many patients might be kicked off Medicaid because of new eligibility and work requirements. The federal government is pulling back on payments for emergency services for undocumented people, meaning the county will have to foot more of the bill. The White House did not respond to a request for comment. Department of Health Services officials said they expect to lose $750 million per year by 2028. By then, the agency's budget deficit is projected to have ballooned to $1.85 billion. In an attempt to pump more cash into the system, L.A. County supervisors voted on Tuesday to increase a parcel tax first approved by voters in 2002, which is expected to raise an additional $87 million for the county's trauma care network. After a long debate Tuesday, Supervisors Holly Mitchell and Lindsey Horvath worked to direct $9 million of the parcel tax money to Martin Luther King Jr. Community Hospital, a private hospital that serves as a critical safety net for South Los Angeles residents who would otherwise find themselves in a medical desert. Without that cash infusion from the county, the cuts in Trump's bill would have put the hospital at risk of closing, since the majority of patients in its emergency room are on Medicaid, said Elaine Batchlor, Martin Luther King's chief executive officer. 'If they've lost their Medicaid coverage, we simply won't get paid for those patients,' she said. Martin Luther King replaced a county hospital that closed after losing national accreditation in 2005 because of serious medical malpractice, landing it the nickname 'Killer King.' 'The fact that that hospital closed in the first place I think is criminal, and I intend to do all I can to protect the integrity of the services,' said Mitchell, whose district includes the hospital and who pushed for it to get a cut of money from the parcel tax increase. Local health providers said that changes at the state level have created additional uncertainty. The state budget for this fiscal year freezes enrollment in Medi-Cal, California's version of Medicaid, for undocumented immigrants ages 19 and older starting in January. Medi-Cal recipients ages 19 to 59 will have to pay a $30 monthly premium beginning July 1, 2027. 'Most families [we serve] are making about $2,400 to $2,600 a month. They're going to have to choose between paying their Medi-Cal fees for a family of four — that's $120 a month — or paying rent or paying for food,' said Jim Mangia, head of St. John's Community Health, who said the cuts will disrupt care for tens of thousands of low-income residents. The St. John's clinic, which gets most of its revenue from Medi-Cal reimbursements, serves more than 120,000 patients a year, most of whom live below the federal poverty line. If the clinic doesn't find a way to replace the lost revenue, Mangia warned, services will have to be reduced. The clinic recently started treating immigrant patients in their homes after realizing they had been skipping appointments because they feared being arrested by federal immigration agents. 'Then what we're looking at is closing several health centers,' said Mangia. 'We're looking at laying off hundreds of staff.' At Venice Family Clinic, a community health center that serves nearly 45,000 patients annually, 80% of patients rely on Medi-Cal. Roughly half the clinic's revenue comes from Medi-Cal reimbursements. Dr. Mitesh Popat, a family physician and head of the clinic, said that federal policy changes — especially more frequent paperwork and added work requirements — will likely push eligible patients off of Medi-Cal. He said the clinic is exploring ways to expand support for patients to navigate the paperwork and keep their coverage. 'This puts a bunch of barriers in the way of people who already have enough challenges in life,' Popat said. 'They're trying to make it, trying to survive, trying to put food on the table.'
